What is Atomic AI?
Atomic AI operates at the intersection of artificial intelligence and biotechnology, specializing in the discovery of RNA-targeted small molecules and RNA-based medicines. By integrating state-of-the-art deep learning models with rigorous in-house wet-lab assays, the company has established a unique research infrastructure. This dual-pronged approach allows Atomic AI to identify highly potent and selective therapeutics, positioning it as a critical partner for pharmaceutical companies and research institutions seeking to navigate the complexities of RNA-based drug development. The firm's market position is defined by its ability to transform raw biological data into actionable therapeutic candidates, effectively shortening the discovery cycle for next-generation medicines.
How much funding has Atomic AI raised?
Atomic AI has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from 8VC, Playground, AME Cloud Ventures, The Factory HQ, and Greylock Partners
Key Investors in Atomic AI
8VC
8VC is a prominent technology investment firm that backs industry-transforming companies, with a specific focus on smart enterprise platforms across healthcare and Bio-IT sectors.
Playground
Playground Global invests in founders harnessing frontier technologies, providing world-class expertise to help companies in artificial intelligence and life sciences achieve their full potential.
AME Cloud Ventures
Led by Jerry Yang, AME Cloud Ventures focuses on technology-heavy companies that build infrastructure and value chains around data, supporting innovation across the data stack.
What's next for Atomic AI?
With this major enterprise-level funding, Atomic AI is poised to scale its computational capabilities and expand its wet-lab operations. The strategic focus will likely shift toward validating its lead candidates in clinical settings and forging deeper partnerships with global pharmaceutical entities. As the company matures, the integration of its AI-driven platform into broader drug discovery workflows will be essential for maintaining its competitive edge. Investors are looking for the firm to demonstrate long-term scalability in its therapeutic pipeline, potentially setting a new standard for how AI-native biotech companies approach the high-stakes environment of drug discovery and development.
See full Atomic AI company page
